Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024年3月7日 - 8:40AM
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an
innovative life sciences technology company providing mission
critical automation solutions to facilitate the efficient
manufacturing and fast, safe release of healthcare products, today
announced that, effective March 4, 2024, the Compensation
Committee of the Company’s Board of Directors granted non-qualified
stock options to purchase 150,000 shares of the Company’s Class A
common stock (“Common Stock”) and 75,000 restricted stock units
(“RSUs”) to a new employee under the Company’s 2023 Inducement
Plan, as amended (the “2023 Inducement Plan”).
The 2023 Inducement Plan is used exclusively for
the grant of equity awards to individuals who were not previously
an employee of the Company, as an inducement material to such
individual's entering into employment with the Company, pursuant to
Rule 5635(c)(4) of the Nasdaq Listing Rules.
The options have an exercise price
of $0.99 per share, which is equal to the closing price
of the Common Stock on March 4, 2024 (the “Grant Date”).
Twenty-five percent (25%) of the shares of Common Stock underlying
the options will vest and become exercisable on the first
anniversary of the Grant Date, and 1/48th of the shares of Common
Stock underlying the options will vest and become exercisable
each month thereafter, in each case, subject to such employee's
continued employment on each vesting date. The RSUs will vest
annually over a three-year period, with one-third of the RSUs
vesting on each anniversary of the Grant Date, subject to such
employee's continued employment on each vesting date. The options
and RSUs are subject to the terms and conditions of the 2023
Inducement Plan, and the terms and conditions of the stock option
and RSU agreements covering the grants.
About Rapid Micro
Biosystems
Rapid Micro Biosystems is an innovative life
sciences technology company providing mission critical automation
solutions to facilitate the efficient manufacturing and fast, safe
release of healthcare products such as biologics, vaccines, cell
and gene therapies, and sterile injectables. The Company’s flagship
Growth Direct system automates and modernizes the antiquated,
manual microbial quality control (“MQC”) testing workflows used in
the largest and most complex pharmaceutical manufacturing
operations across the globe. The Growth Direct system brings the
quality control lab to the manufacturing floor, unlocking the power
of MQC automation to deliver the faster results, greater accuracy,
increased operational efficiency, better compliance with data
integrity regulations, and quicker decision making that customers
rely on to ensure safe and consistent supply of important
healthcare products. The Company is headquartered and has U.S.
manufacturing in Lowell, Massachusetts, with global locations in
Lexington, Massachusetts, Switzerland, Germany, and the
Netherlands. For more information, please visit
www.rapidmicrobio.com or follow the Company on X (formerly known as
Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
investors@rapidmicrobio.com
Media Contact:
media@rapidmicrobio.com
Rapid Micro Biosystems (NASDAQ:RPID)
過去 株価チャート
から 1 2025 まで 2 2025
Rapid Micro Biosystems (NASDAQ:RPID)
過去 株価チャート
から 2 2024 まで 2 2025